The first patient is a milestone for any clinical trial. The joint work of the clinical investigators, the study centres and the project managers of IHF GmbH begins with the first patient. This time, the Ludwigs-Maximilians-University Clinic kicked off the project: The clinical trial team of Prof. Dr. Steffen Massberg admitted the first patient to the study. REBOOT PARADOX is the first clinical study to systematically benchmark therapies for paradoxical aortic valve stenosis. Previous investigations have shown that the prognosis for patients with reduction of the aortic valve area can be significantly improved by aortic valve replacement. However, there is still no sufficient database for a reliable recommended treatment. Directed by Prof Julinda Mehilli (Munich), the clinical study focuses for the first time on the particular medical conditions of paradoxical aortic valve stenosis. The study includes two patient groups, one of which is drug-adjusted and one has an artificial heart valve. The IHF GmbH team would like to wish the very first and future patients an early recovery and an improved health with a great quality-of-life.
First results introduced during the 88th annual meeting of the DGK in Mannheim byProf. Uwe Zeymer, Chairman of the Foundation Institute for Myocardial Infarction Research and Principal Investigator of the GULLIVE-R study.Read more
Dr. Matthieu Godin and his study team from Clinique Saint Hilaire in Rouen, and Dr. Christophe Robin and his study team from Clinique Convert, of Bourg en Bresse are pleased to announce the successful enrollment of their first patient.Read more
The design paper of the PASSPORT-HF study has been published.Read more